LH/FSH, Testosterone, Prolactin, and Ferritin in PCOS Patients in Jordan

NCT07112768 | Completed DMC

• 1 other identifier: Al-Ahliyya Amman University 1
• Study Type: observational
• Target: 140
• Locations: 1 country
• Sites: 1

Brief Summary

Polycystic Ovary Syndrome (PCOS) is a prevalent endocrine disorder impacting women of reproductive age. Characterized by chronic anovulation, hyperandrogenism, and the presence of multiple small ovarian cysts. Despite its widespread occurrence, a comprehensive study particularly within the Jordanian population remains limited. Aim of the study: The study aimed to assess the serum levels of the Luteinizing hormone (LH), Follicle stimulating hormone (FSH), LH/FSH ratio, Testosterone, Prolactin, and Ferritin in Jordanian women diagnosed with PCOS

Conditions

PCOS (Polycystic Ovary Syndrome)

Outcome Measures

Primary Outcomes (2)

• Hormonal level

  Serum levels of LH, FSH, testosterone, prolactin

  3 months

• Biochemical marker

  Serum level of Ferrtin

  3 months

Study Arms (2)

Control group

control group (n=60), consisting control women aged 22-41 years

Diagnostic Test: Serum levels of LH, FSH, testosterone, prolactin, and ferritin

PCOs group

the study group (n=80), comprising women aged 20 to 41 years who were diagnosed with PCOS based on the Rotterdam criteria (2003) as assessed by obstetric and gynecology specialist

Diagnostic Test: Serum levels of LH, FSH, testosterone, prolactin, and ferritin

Interventions

Serum levels of LH, FSH, testosterone, prolactin, and ferritin DIAGNOSTIC_TEST

Measurement of both hormonal and biochemical markers in Jordanian PCOs females, including Serum levels of LH, FSH, testosterone, prolactin, and ferritin)

Also known as: LH, FSH, testosterone, prolactin, ferritin

Control group; PCOs group

Eligibility Criteria

• Age: 20 Years - 45 Years
• Gender Eligibility Details: (n=140) females were included in the current study which were subdivided into two groups: the study group (n=80), comprising women aged 20 to 41 years who were diagnosed with PCOS based on the Rotterdam criteria (2003) as assessed by obstetric and gynecology specialist \[14\]; and the control group (n=60), consistening control women aged 22-41
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

(n=140) females were included in the current study which were subdivided into two groups: the study group (n=80), comprising women aged 20 to 41 years who were diagnosed with PCOS based on the Rotterdam criteria (2003) as assessed by obstetric and gynecology specialist ; and the control group (n=60), consistening control women aged 22-41

You may qualify if:

• Age 20-45 PCOS diagnosed females Jordanian

You may not qualify if:

• younger than 20 older than 45 Non -Jordanian

Sponsors & Collaborators

• Future University in Egypt: lead

Study Sites (1)

Al-Ahliyya Amman University

Amman, Amman Governorate, Jordan

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Five milliliters of venous blood were drawn and placed in simple test tubes for sample collection.

MeSH Terms

Conditions

Polycystic Ovary Syndrome

Condition Hierarchy (Ancestors)

Ovarian Cysts; Cysts; Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases; Gonadal Disorders; Endocrine System Diseases

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Target Duration: 3 Months
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant professor of clinical Pharmacy

Study Record Dates

• First Submitted: August 2, 2025
• First Posted: August 8, 2025
• Study Start: January 2, 2024
• Primary Completion: April 10, 2024
• Study Completion: April 22, 2024
• Last Updated: August 8, 2025

Record last verified: 2025-08

Locations

JO (1)